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Abstract
Background: Spirometry is commonly accepted as the gold standard for the diagnosis of COPD, but the reality
remains that quality assured spirometry is not or cannot be provided universally around the globe. Adding PEF
measurement to a screening questionnaire may rule out airflow limitation compatible with COPD rationalizing
spirometry testing.
Methods: We conducted a cross-sectional survey in a sample of individuals 40–80 yrs. old in Dubai, UAE. They were
invited to answer a short socio-demographic questionnaire including a report on current, past history of smoking,
and had PEF measured, then they conducted spirometry to identify airflow limitation compatible with COPD.
Results: Overall, 525 (91.0%) participants performed PEF and spirometry (68% male, with a mean age of 59 years,
17% UAE Nationals), 24% reported smoking of different sorts. Overall, 68 participants (12.9%, 95% C.I. 10.3% to
16.1%) had airflow limitation compatible with COPD. PEFR alone identified 141participants with airflow limitation
compatible with COPD, with specificity of 80% and sensitivity of 73.5%.
Conclusions: PEFR could be an easy, cheap, and non-biased tool to assist with the case-finding of COPD before
confirmation with spirometry.
Background
Undiagnosed airflow limitation (airway obstruction) is
common in the general population and is associated with
impaired health and functional status [1]. Chronic ob-
structive pulmonary disease (COPD) is a leading cause
of chronic morbidity and mortality worldwide [2]. Ac-
cording to the Global Burden of Disease Study in 2010,
COPD was the sixth leading cause of death worldwide
in 2001, but moved to third in 2010, just behind ische-
mic heart disease and stroke [2]. Furthermore, COPD
prevalence is greatly underestimated, since it is usually not
diagnosed until it is clinically apparent and moderately
advanced. It is currently estimated there are 328 million
people with COPD in the World [3].
In the Middle East & North Africa (MENA) region,
epidemiological data on COPD are scarce. The BREATHE
study, a recently conducted international survey in 2012,
described the prevalence of symptoms that could be
COPD-related in each MENA country. The lowest age-
and gender-adjusted prevalence was in the United Arab
Emirates (UAE) with 1.9% of participants (95% CI 1.4 to
2.4) [4]. In another study conducted in 2010 by Alzaabi
et.al., COPD prevalence in those 40–80 years old in
Abu Dhabi, UAE was also low with 3.7% (95% CI 2.0
to 5.3) [5].
Earlier COPD diagnosis should produce substantial
individual health and Public Health benefits [6,7] and
therefore there is an pressing need for case-finding
strategies to support the early diagnosis of COPD. Case
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finding can be active (e.g. targeting smokers over 40 years
of age with case-finding questionnaires) or passive (e.g.
waiting for people to go to the doctor) [8,9].
Spirometry is commonly accepted as the gold stand-
ard for the diagnosis of COPD [10,11]. The American
Association for Respiratory Care supports the National
Lung Health Education Program (NLHEP) to promote
the appropriate use of spirometry by primary health care
practitioners for the detection of COPD in adult smokers
[12]. The reality remains that quality assured spirometry
cannot be provided universally around the globe. Another
problem that spirometers may not be available or used
properly in primary health care due to financial limitations
or limited availability of expert technicians or clinicians to
perform the procedure [7].
A workshop organized by the US National Institutes
of Health (National Heart, Lung, and Blood Institute
Division of Lung Diseases (DLD)) identified an urgent
need to develop and test a strategy for active case finding
of COPD for those who have clinically significant COPD
(specifically those with a forced expiratory volume in 1 s
(FEV1) ≤ 60% predicted). They suggested this should
include a combination of initial risk assessment (via a
questionnaire) followed by a simple measurement of peak
expiratory flow (PEF) and, as appropriate, full diagnostic
pre-bronchodilator_(BD) and post-BD spirometry [13].
Validated questionnaires facilitate early recognition
and diagnosis of COPD. Perez-Padilla et al., concluded that
adding PEF measurement to a screening questionnaire
may rule out severe to very severe COPD without the
need for pre- and post-BD spirometry testing. In a recent
multicenter study, Burden of Obstructive Lung disease
(BOLD), Jithoo and colleagues concluded that the use of
peak expiratory flow (PEF), with a 2.2 L.s-1.m−2 threshold
was a simple, cost effective initial screening tool for con-
ducting COPD case-finding in adults aged ≥40 years [7].
Our study aimed to assess the value of PEFR as a screen-
ing tool by comparing it to spirometry.
Methods
We conducted a cross sectional study in Dubai, UAE, in
collaboration with the Emirates Cardiac Society during
the World Heart Day campaign in September 2012. Par-
ticipants were recruited from five primary health care cen-
ters during routine clinic visits, from two large shopping
malls in Dubai, and from Dubai Industrial city, (a large,
varied workplace) aiming to represent a valid sampling
frame of the local population. This study was approved by
the Dubai Health Authority (DHA) research and ethics
committee.
Study population
Adult participants 18 years and older were offered screen-
ing for medical conditions with measurements of height,
weight, blood pressure, Hemoglobin A1c (Hb A1c), lipid
profile, and carbon monoxide (CO). Overall, a total of
1,607 people were screened for cardiopulmonary risk fac-
tors and participants 40 years and older were invited for
COPD screening including of a short socio-demographic
questionnaire, PEFR, and spirometry.
Questionnaire
Data were collected via face-to-face interview, and in-
cluded data about current and past smoking cigarettes
and other local products like Midwakh (a small pipe for
smoking tobacco of Arabian origin, (Figure 1) which was
traditionally smoked by Bedouins and sailors in the
UAE, water pipe and other. We also assessed exposure
to domestic biomass and coal pollution (cooking/heat-
ing), and occupational exposure to dust [14].
Peak expiratory flow rate (PEFR)
We measured peak expiratory flow rate (PEFR) in all par-
ticipants. To correlate with height, PEFR measurements
were divided by height squared (m2) and expressed in
units of L.s−1.m-2. [7].
Spirometry
Spirometry was performed by using a handheld spirometer
(Vitalograph alpha and one alpha, Vitalograph Ltd UK).
The accuracy of the devices were calibrated against our
laboratory spirometer (Master screen Care Fusion Cor-
poration, Delaware, USA). Pre-bronchodilator (pre-BD)
spirometry was performed to identify airflow limitation
(ratio of FEV1/FVC < 0.70) compatible with COPD. The
severity of airflow limitation was staged according to
the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines as mild, moderate, severe, and
Figure 1 Midwakh.
Mahboub et al. BMC Research Notes 2014, 7:241 Page 2 of 7
http://www.biomedcentral.com/1756-0500/7/241
very severe according to FEV1 (% predicted) as >80%,
50-79%, 30-49%, or < 30% respectively.
Statistical methods
Data was reviewed by a central committee, and values
that were considered as potential errors or outliers were
individually addressed. Comprehensive tabulations with
ranges, mean and standard deviation of all predefined
quantitative variables, and percentages of all predefined
qualitative variables, were conducted.
The results for each variable are shown as the mean
with standard deviation in the case of continuous vari-
ables, and the number of cases for each category and fre-
quency regarding the total number of responses in the
case of categorical variables. The prevalence of airflow
limitation and its 95% confidence interval in total and by
subgroups were calculated. The statistical significance of
variables was assessed first with ANOVA and then a bilat-
eral test for continuous variables, and a Chi-squared test
for categorical variables. In a final logistic multivariate
analysis, the reference categories were: age between 40 –
49 years; female; never smoker; and University degree edu-
cation. In all analyses, a P value below 0.05 was considered
to be statistically significant.
Results
A STROBE flow-chart of participants is presented in
(Figure 2), indicating the sequential recruitment of indi-
viduals. As stated, 1,607 individuals participated from
the five primary health care centers, the two shopping
malls, and Dubai Industrial City. Of them, 1,410 partici-
pants had a minimum data set, and of these577 partici-
pants were 40 years and older. These 577 participants
were invited to perform PEFR, then spirometry. Overall,
525 (91.0%) conducted quality controlled pre-BD spir-
ometry. Participants were 68% male, with a mean age of
59 years, 17% were UAE Nationals, and 24% reported
smoking of some sorts.
Table 1 shows the numbers of participants who might
have airflow limitation compatible with COPD by using
PEFR measurements (using proposed method PEFR
(L.s-1.m−2) (≤1.3, >1.3–1.8, >1.8–2.2, >2.2 L.s-1.m-2).
By using spirometry overall 68 participants (12.9%,
95% C.I. 10.3% to 16.1%) had airflow limitation compatible
with COPD. Figure 3 shows the prevalence of COPD by
gender and age group.
Participants who had airflow limitation compatible
with COPD were older than those who had normal lung
function (mean ± SD) 52 ± 8.8 years vs. 49.2 ± 7.7 years,
Figure 2 STROBE flow-chart of participants.
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p = 0.006). A comparison of the demographic character-
istics of participants, smoking prevalence, exposure to
domestic biomass, and occupational exposure to dust
between participants who had airflow limitation compat-
ible with COPD and those with normal lung function is
shown in Table 2. Occupational exposure to dust was
associated with airflow limitation compatible with COPD
(p = 0.006).
In (Table 3) we present the crude and the adjusted
risks for COPD (OR and 95% confidence interval). In bi-
variate analysis, only increasing age and previous occu-
pational exposure to dust were associated with COPD
(both p < 0.05). In the multivariate analysis, there was a
trend for older, non-UAE nationals, less educated, and
smokers to have high risk of COPD, but again only occu-
pational exposure to dust remained statistically significant.
Participants who had airflow limitation compatible with
COPD were categorized by severity as 33.3% mild (GOLD
stage I) 55.5% moderate (GOLD stage II) 11.1% severe
(GOLD stage III), and none with very severe COPD
(GOLD stage IV) as showed below in (Table 4).
We found that out of 68 participants with COPD in our
study, 50 participants would have been identified as COPD
by using a proposed threshold of PEFR of 2.2 L.s-1.m−2;
Hence PEF measurements resulted in 73.5% sensitivity
and 80% specificity for the diagnosis of COPD.
In (Table 5) there were no clinically or statistically sig-
nificant differences observed by gender, age, smoking sta-
tus or height in COPD patients as diagnosed by PEFR.
Discussion
We found that the measurement of pre-BD PEF as a
screening tool in adults with a high risk of COPD was able
to identify individuals who were most likely to benefit
from confirmatory spirometry.
Our results support previous work by Jithoo et al.,
who suggested using a PEFR threshold of < 2.2 L.s-1.m−2.
There were no differences observed in gender, age, smok-
ing status or height among in people with COPD with
PEFR values above or below the threshold emphasizing
the value of this approach in COPD case finding. Further
research is awaited and issues that need to be addressed
have been raised [15].
In our study, PEF measurements resulted in 73.5% of
sensitivity and 80% specificity. This is comparable to
Jitho’s study (83-84%% sensitivity overall and 91–93%
sensitivity for severe COPD). That difference could be
due to different type of populations and number of partici-
pants. Ours was a single location study in Dubai with 525
participants while Jitho et al., was based on population
samples from 14 different centers comprising 10,712
participants around the world [7].
Our study concluded that previous occupational ex-
posure to dust was associated with airflow limitation
compatible with COPD. Previous studies [16,17] found
an association between environmental exposures, occu-
pational and biomass exposures, and the prevalence/in-
cidence of COPD. UAE is a fast growing country with
many new construction sites, which could explain and
support our finding of the statistically significant rela-
tionship between occupational exposure and COPD,
Figure 3 Prevalence of COPD (and 95% C.I.) by gender and age group.
Table 1 Participants PEFR results according proposed
method PEF per m2
Pre-BD PEF per Ht2 (L.s-1.m−2) results N= %
≤1.3 40 7.6%
>1.3–1.8 44 8.3%
>1.8–2.2 57 10.6%
>2.2 384 73.1%
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which is worth further exploration in future studies with a
larger sample.
We were unable to confirm smoking or biomass expos-
ure findings. However, this factor had been measured
using a simple question during the interview. Moreover,
due to the relatively low number of subjects with COPD
in the study, the power of our study might not have been
enough to detect small effects of smoking or biomass
exposure.
Although PEF has not been well recognized for COPD
diagnosis, it has been proposed as a good indicator of
COPD mortality risk in hospital [18] and of quality of
life. It has also been explored in the emergency room as-
sessment of COPD exacerbation [19] and with good reli-
ability for home assessment in patients with COPD [20].
Table 2 Demographic characteristics of participants
Variable COPD
(n = 68)
Normal lung
function (n = 457)
P
Male gender, n (%) 47 (69.1%) 311 (68.1%) 1.000
Age in years,
mean ± SD
52 (±SD 8.8) 49.2 (SD 7.7) 0.006
Nationality, n (%) 0.488
UAE 9 (13.2%) 79 (17.3%)
Other 59 (86.8%) 378 (82.7%)
Height in cm,
mean ± SD
164.9 (±SD 8.6) 164.82 (±SD 8.7) 0.890
Weight in kg,
mean ± SD
76.3 (±SD 12.9) 77 (±SD15.4) 0.737
BMI in kg/m2,
mean ± SD
28.4 (±SD 4.6) 28.4 (±SD 4.7) 0.902
Education, n (%) 0.397
Primary 34 (50.0%) 231 (50.5%)
Diploma 3 (4.4%) 24 (5.3%)
College 30 (44.1%) 174 (38.1%)
Higher Education 1 (1.5%) 28 (6.1%)
Any smoking, n (%) 17 (25.0%) 111 (24.3%) 0.881
Cigarette smoking
Smokers, n (%) 18 (26.4%) 115 (25.2%) 1.000
Number of
cigarettes/day,
mean ± SD
14.4(±SD 11) 12 (±SD 10.4) 0.493
Midwakh smokers, n (%) 0 (0.0%) 1 (0.3%) 1.000
Water pipe smoking
Smokers, n (%) 1 (3.4%) 13 (3.9%) 1.000
Heads of waterpipe/
month, mean ± SD
4.1 (±SD 22.3) 1.1 (±SD 7.5) 0.098
Other Smoking
Smokers, n (%) 1 (3.4%) 3 (0.9%) 0.294
Other tobacco per
week, mean ± SD
0.9 (±SD 5.1) 0.2 (±SD 1.9) 0.082
Exposure to domestic
biomass and coal
pollution (cooking/
heating), n (%)
12 (17.6%) 52 (11.4%) 0.162
Occupational exposure
to dust, n (%)
26 (38.2%) 102 (22.3%) 0.006
Hospital admissions due
to pulmonary problems
in childhood, n (%)
4 (5.9%) 20 (4.4%) 0.536
Table 3 Crude and adjusted risk of COPD (OR and 95%
confidence interval)
Variable Bivariate Adjusted
Male gender 1.05 (0.61-1.89) 0.93 (0.41-1.70)
Age in years
40-49 yrs. 1 1
50-59 yrs. 1.67 (0.95-2.93) 1.66 (0.94-2.95)
60-69 yrs. 1.70 (0.76-3.83) 1.60 (0.70-3.66)
70-80 yrs. 3.34 (0.84-13.28) 4.36 (1.03-18.48)
UAE National 0.76 (0.39-1.43) 0.68 (0.30-1.53)
Education
Primary 1 1
Diploma 0.85 (0.24-2.97) 0.89 (0.25-3.19)
College 1.17 (0.69-1.99) 1.15 (0.66-2.02)
Higher Education 0.24 (0.03-1.84) 0.27 (0.03-2.69)
Smoking any 1.04 (0.58-1.87) 1.10 (0.59-2.06)
Cigarette user 1.05 (0.57-1.94)
Midwakh user 0.92 (0.84-0.95)
Water pipe user 0.87 (0.11-6.9)
Other user 3.77 (0.38-37.40)
Biomass exposure 1.67 (0.84-3.32)
Occupational exposure 2.16 (1.26-3.68) 2.07 (1.20-3.59)
Respiratory infection in childhood 1.37 (0.45-4.12)
Table 4 Clinical characteristics of participants
Variable COPD
(n = 68)
Normal lung
function (n = 457)
p
FEV1 pre-BD, mean ± SD 1.9 (±SD 0.6) 2.7 (SD 0.6) < 0.001
FVC pre-BD, mean ± SD 3.2 (±SD 1.0) 3.1 (SD 1.0) 0.700
FEV1/FVC pre-BD,
mean ± SD
0.60 (±SD 0.09) 0.86 (SD 0.09) < 0.001
PEFR pre-BD,
mean ± SD
208.9 (±SD 146.0) 502.1 (SD 220.7) < 0.001
Severity of airflow
limitation, %
Mild 33.3% - -
Moderate 55.5%
Severe 11.1%
Very Severe 0.0%
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Advantages and limitations
Our study has some strength, including novelty given
the scarcity of previous spirometry studies in our envir-
onment and the large response rate. However, a main
limitation of our study is the use of pre-bronchodilator
spirometry for defining airflow limitation compatible with
COPD. As a consequence, given that all major COPD
guidelines [1,10,15] recommend post-BD spirometry,
some subjects with asthma with fully reversible obstruc-
tion could have been falsely classified as having COPD
leading to overestimation of COPD patients. Other limi-
tations in our study include the following: participants
were volunteers and hence a potential selection bias
could be present; the relatively small sample size pre-
vented us from conducting further subgroup analysis,
although our multivariate analysis appears robust.
Conclusion
PEFR, with or without a questionnaire, could be used as
a simple tool in the Primary health care setting to screen
smoker of more than 40 years age for airflow limitation
compatible with COPD.
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